PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-18
SponsorJeffrey Pernica
About this trial
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.
Eligibility criteria
Qualifiers
Tachypnoea measured at triage (>60 bpm for age <1, >50 for 1-2 years of age, >40bpm for 2-4 years of age, and >30bpm for >4 years of age)
Cough on exam or by history
Increased work of breathing on exam
Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP
Disqualifiers
Cystic Fibrosis
Anatomic Lung Disease
Bronchiectasis
Chronic Lung Disease requiring home oxygen or home ventilation
Trial design
Treatments tested in this trial
- The novel care pathway intervention
- Usual Care Alone
Treatment groups
698 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jeffrey Pernica
Lead sponsor
McMaster University
Sponsor institution
Source ClinicalTrials.gov